Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 272

1.

Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E; American Society for Bone and Mineral Research.

J Bone Miner Res. 2007 Oct;22(10):1479-91.

2.
3.

Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.

Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Al Mardini M, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, St-Marie LG, Brown J, Evans AW, Rios L, Compston JE; Canadian Association of Oral and Maxillofacial Surgeons.

J Rheumatol. 2008 Jul;35(7):1391-7. Epub 2008 Jun 1. Erratum in: J Rheumatol. 2008 Oct;35(10):2084. J Rheumatol. 2008 Aug;35(8):1688.

PMID:
18528958
4.

Osteonecrosis of the jaw and the role of bisphosphonates: a critical review.

Silverman SL, Landesberg R.

Am J Med. 2009 Feb;122(2 Suppl):S33-45. doi: 10.1016/j.amjmed.2008.12.005. Review.

PMID:
19187811
5.

Osteonecrosis of the jaw: an update and review of recommendations.

Novince CM, Ward BB, McCauley LK.

Cells Tissues Organs. 2009;189(1-4):275-83. doi: 10.1159/000152915. Epub 2008 Sep 1. Review.

PMID:
18765930
6.
7.

Bisphosphonate associated osteonecrosis of the jaw.

Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Lentle B, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Mardini MA, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, Ste-Marie LG, Brown J, Evans AW, Rios L, Compston JE; Canadian Taskforce on Osteonecrosis of the Jaw.

J Rheumatol. 2009 Mar;36(3):478-90. doi: 10.3899/jrheum.080759. Review.

PMID:
19286860
8.

Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment.

Fehm T, Felsenberg D, Krimmel M, Solomayer E, Wallwiener D, Hadjii P.

Breast. 2009 Aug;18(4):213-7. doi: 10.1016/j.breast.2009.07.001. Epub 2009 Aug 3. Review.

PMID:
19651512
9.

Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.

Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S.

Osteoporos Int. 2007 Oct;18(10):1363-70. Epub 2007 Jun 28.

PMID:
17598065
10.

Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.

King AE, Umland EM.

Pharmacotherapy. 2008 May;28(5):667-77. doi: 10.1592/phco.28.5.667. Review.

PMID:
18447663
11.

Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.

La Verde N, Bareggi C, Garassino M, Borgonovo K, Sburlati P, Pedretti D, Bianchi C, Perrone S, Mihali D, Cobelli S, Mantica C, Rizzo A, Farina G.

Support Care Cancer. 2008 Nov;16(11):1311-5. doi: 10.1007/s00520-008-0484-3. Epub 2008 Jul 29.

PMID:
18663482
12.

Osteonecrosis of the jaw in patients on bisphosphonate treatment. review of literature with contribution of a case of multiple myeloma.

Goranova-Marinova VS, Pechalova-Petrova PF, Goranov SG.

Folia Med (Plovdiv). 2009 Oct-Dec;51(4):53-7.

PMID:
20232660
13.

Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates.

Gebara SN, Moubayed H.

Am J Health Syst Pharm. 2009 Sep 1;66(17):1541-7. doi: 10.2146/ajhp080251. Review.

PMID:
19710437
14.

Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.

Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY.

Bone. 2008 May;42(5):841-7. doi: 10.1016/j.bone.2008.01.003. Epub 2008 Jan 18. Review.

PMID:
18314405
15.

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.

Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA.

J Clin Oncol. 2005 Dec 1;23(34):8580-7.

PMID:
16314620
16.

Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases.

Grant BT, Amenedo C, Freeman K, Kraut RA.

J Oral Maxillofac Surg. 2008 Feb;66(2):223-30. doi: 10.1016/j.joms.2007.09.019.

PMID:
18201600
17.

Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.

Kunchur R, Need A, Hughes T, Goss A.

J Oral Maxillofac Surg. 2009 Jun;67(6):1167-73. doi: 10.1016/j.joms.2009.02.004.

PMID:
19446200
18.

[Bisphosphonates and osteonecrosis of the jaws].

Urade M.

Clin Calcium. 2007 Feb;17(2):241-8. Review. Japanese.

PMID:
17272882
19.

Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

Mavrokokki T, Cheng A, Stein B, Goss A.

J Oral Maxillofac Surg. 2007 Mar;65(3):415-23.

PMID:
17307586
20.

Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons.

Khan AA, Rios LP, Sándor GK, Khan N, Peters E, Rahman MO, Clokie CM, Dore E, Dubois S.

J Rheumatol. 2011 Jul;38(7):1396-402. doi: 10.3899/jrheum.100221. Epub 2011 Apr 15.

PMID:
21498483

Supplemental Content

Support Center